Primary dysmenorrhoea

Active Ingredient: Mefenamic acid

Indication for Mefenamic acid

Population group: women, only adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Therapeutic intent: Palliative intent

For this indication, competent medicine agencies globally authorize below treatments:

500 mg three times daily


Dosage regimens

Oral, 500 milligrams mefenamic acid, 3 times daily.

Detailed description

In dysmenorrhoea to be administered at the onset of menstrual pain and continued according to the judgement of the physician.

500 mg three times daily


Dosage regimens

Rectal, 500 milligrams mefenamic acid, 3 times daily.

Active ingredient

Mefenamic acid

Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties.

Read more about Mefenamic acid

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.